"I thought I might be dead in a few months" - Kareem Abdul-Jabbar on getting diagnosed with leukemia
Kareem Abdul-Jabbar, born in 1947, is nearing 80. Despite that advanced age, he still seems to be going strong. Basketball fans should appreciate that, not just for his longevity, but because one story about the sports icon shows how quickly it can all end.
In 2011, the Hall of Famer shared his reaction to a leukemia diagnosis — news that hit like a thunderbolt.
Fearing the worst
In November 2009, Abdul-Jabbar revealed he was diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia, a blood and bone marrow cancer.
The two-time Finals MVP said he had received the devastating news in December 2008. While shocking on its own, it hit harder because of memories of his close friend Bruno Kirby.
The actor, known for "When Harry Met Sally…" and "Good Morning, Vietnam," died from leukemia complications in August 2006, "within 30 days" of his diagnosis, Kareem recalled.
Of course, every case is different, and disease progression varies. Still, the Los Angeles Lakers legend admitted he instantly feared the worst when he received the same diagnosis, mainly because he "really had no understanding" of what he was dealing with.
"I thought I might be dead in a few months," said Abul-Jabbar, per ESPN.Kareem's battle
Fast forward to 2011, Kareem took to X (formerly Twitter) with hopeful news: he was cancer-free — a statement he later corrected.
"You're never really cancer-free and I should have known that," he said. "My cancer right now is at an absolute minimum… It's not life-threatening at this point in my life."
Following a similar approach to former superstar teammate Magic Johnson's powerful handling of his HIV diagnosis, Abdul-Jabbar faced his own illness head-on.
For instance, the New York native became a spokesperson for Novartis, makers of Gleevec, the drug that transforms chronic myeloid leukemia into a manageable condition and boosts survival rates.
"Medical science has made great strides over the last 20 years," Kareem noted. "People in my position are able to live their lives to the fullest. I'm very grateful for that. I'm lucky that they caught it in enough time, and I've responded well to the medication. If not for the success that medicine has made, I might be part of a much different story right now."
It wasn't the only time cancer challenged him.
In 2020, Abdul-Jabbar revealed he'd been diagnosed with prostate cancer eleven years earlier. And while he fought it again, the now 78-year-old didn't forget those in the same fight.
Kareem acknowledged that as an NBA star, he had access to top-tier medical care — something many in the Black community lack.
"While I'm grateful for my advantages, I'm acutely aware that many others in the Black community do not have the same options and that is my responsibility to join with those fighting to change that," he wrote, per Good Morning America. "Because Black lives are at risk. Serious risk."
Abdul-Jabbar was always the vocal leader in the Showtime Lakers locker room — a voice he clearly hasn't lost, even with adversity testing him time and again.This story was originally reported by Basketball Network on Jul 20, 2025, where it first appeared.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
6 minutes ago
- Medscape
A Life on the Line and $250K in Debt Amid Insurer Denials
The diagnosis came just as Nathan Kirkland and his wife were preparing for the birth of their second child in April 2024. Tests showed Kirkland, then 35 years, had intrahepatic cholangiocarcinoma, a rare form of cancer that develops in parts of the bile ducts housed within the liver. Kirkland's only chance for a cure was a liver transplant, but his tumor was too large to meet the criteria for the surgery. 'Cholangiocarcinoma just isn't a cancer most people come out on the other side of,' Kirkland told Medscape Medical News . 'The doctor said to me, 'Don't plan on seeing your daughter born in a few short months.'' Kirkland and his family Devastated, but determined to fight, Kirkland started a chemotherapy regimen that month to help shrink the tumor. To improve his chances for a liver transplant, his oncology team also recommended a noninvasive procedure, known as a histotripsy, that uses high-intensity sound waves to precisely target and eliminate liver tumors while avoiding the complications of surgery or radiation. The technique, which the FDA authorized in 2023, has shown a 95% success rate for treating liver lesions. Despite the data and FDA authorization, Kirkland's insurer, Anthem Blue Cross Blue Shield, denied a prior authorization request for the procedure in May. In July, Anthem approved a subsequent request, and Kirkland had his first histotripsy later that month. But this approval shift did not indicate better times ahead for Kirkland. The opposite. Starting in early August, Anthem denied approval for Kirkland's two subsequent histotripsy procedures, calling the procedure 'not medically necessary,' and, in November, reversed its July approval because of a coding issue. Anthem's medical policy considers histotripsy an 'experimental or investigational treatment for liver cancer,' Janey Kiryluik, staff vice president for corporate communications at Anthem's parent company Elevance Health, told Medscape Medical News in a statement. After numerous appeals in the fall of 2024, the insurer upheld its decision not to cover Kirkland's histotripsy procedures. Without coverage, the three procedures cost about $150,000 out of pocket, according to Kirkland. Although the exact frequency remains hard to pin down, coverage denials have become increasingly common among major health insurers, like Anthem, and the rise appears to be fueled, in part, by insurers' use of artificial intelligence (AI) algorithms to review prior authorization requests and then deny claims in batches. In some cases, rates of denials may be 16 times higher when reviewed by AI tools than by humans, according to figures from a recent American Medical Association report. While most denials are ultimately overturned, that can take days, sometimes weeks or months, and delay life-saving cancer care. In a 2024 survey of radiation oncologists, for instance, 30% reported that the prior authorization process harmed their patients, and 7% said it led or contributed to a patient's death. 'Every time insurers create a delay or a hurdle, it potentially complicates care,' said Kirkland's Oncologist, Laura Tenner, MD, MPH, an associate professor in the Division of Oncology and Hematology at the University of Nebraska Medical Center, Omaha, Nebraska. 'There have been some significant delays in prior authorizations and coverage by insurance companies that have delayed care to the point where patients missed out on curative intensive therapy for cancers.' To limit the delays, patients like Kirkland may be left with an impossible choice: Find a way to pay for their care and potentially fall into deep debt or delay their care while fighting the insurance company. Kirkland couldn't wait. In October and November 2024, he underwent two more histotripsies. To cover the cost, Kirkland and his wife exhausted their children's college funds and borrowed money from friends and family. In January 2025, Kirkland received some encouraging news: The procedures, plus the chemotherapy, had killed off enough of his cancer for his medical team to approve him for a liver transplant. 'I was on cloud nine once I got the good news from being cleared for transplant,' Kirkland said. 'I thought 'This is the best news ever! I'm going to be there for my kids.'' Kirkland and his family Kirkland started the transplant testing process. His brother agreed to be his donor, and a transplant date was tentatively set for February 14. But those plans halted abruptly. The family received a letter from Anthem denying coverage for the transplant. In the letter, dated February 6, 2025, Anthem claimed that the requested transplant was 'medically unnecessary.' 'Medical studies do not show that this surgery will improve your short- or long-term health,' Anthem officials wrote in the letter, which Kirkland shared with Medscape Medical News . 'It was a gut punch,' Kirkland said. 'This can't be real.' Denial-Fighting AI Enters the Scene Desperate to get the care he needed, Kirkland and his family turned to social media. By this point, Kirkland's out-of-pocket costs totaled about $250,000. Within days of sharing his story, Kirkland's posts on Facebook and LinkedIn garnered more than 6000 shares. The LinkedIn post even caught the attention of billionaire Mark Cuban who offered to help pay for the transplant. But it was a new AI startup called Claimable that turned the tables for Kirkland's insurance fight. The company, which launched in October 2024, is one of a growing crop of AI-based companies using the technology to help patients and providers analyze health insurance claim denials, uncover issues, and ultimately appeal and overturn denials. Health policy analysts say the new wave of companies is part of a growing 'battle of the bots' as health insurers increasingly use AI to deny claims. 'It's not surprising that new AI companies have sprung up,' said Michelle M. Mello, JD, a health law scholar at Stanford Law School who researches the effects of law and regulation on healthcare delivery. 'On the provider side, there are more denials than people to process them, and one of the things AI tools can do is help figure out which denials are most likely to be overturned if appealed. Often, the reason something is denied is just that information is missing. So having AI systems in place that can figure out, can learn, and can put in that additional information, that seems really valuable.' Claimable does not specialize in cancer cases, but when the company caught wind of Kirkland's story through social media, Warris Bokhari, MD, a former National Health Service physician behind the company, wanted to help. 'We probably spent a couple of hours on the phone with Nathan and then spent the rest of the day working with his brother and his sister to piece together the story,' said Bokhari, who previously led healthcare strategy and innovation across corporate America, including Anthem. 'We went through every test, every imaging result. We went through all of the evidence. And over the course of the day, we basically put together an appeal that was then elevated to visibility at the insurance company.' Bokhari discovered that Anthem had Kirkland's diagnosis wrong on the liver transplant denial. And it wasn't the first time. Anthem had initially misidentified Kirkland's cancer as neuroendocrine cancer, not intrahepatic cholangiocarcinoma, in a previous histotripsy denial. Although the original denial letters and initial appeal letter referred to liver cancer, Kiryluik told Medscape Medical News that the ''neuroendocrine cancer' term was inadvertently inserted by a medical director reviewer from a drop-down screen in place of 'liver cancer' which appears immediately above on the drop-down screen.' But 'this error did not impact the decision,' Kiryluik wrote. The second time occurred in the transplant denial letter from February 6, which listed Kirkland's cancer as hilar primary sclerosing cholangiocarcinoma — also a form of bile duct cancer, but one that develops outside the liver. The crux of Kirkland's appeal, however, was that Anthem was using data from 2004 to support its denial, Bokhari said. This is not unusual. Bokhari has found that many insurance companies rely on poor or out-of-date evidence or inconsistent enforcement of policies to make claim decisions. To unearth such issues, Claimable's AI platform analyzes patients' medical cases alongside clinical evidence, policy details, and appeal precedents in similar cases. The company charges patients about $50 fee for the service. In Kirkland's case, Claimable pointed to studies starting in 2018 that showed outcomes for patients with cholangiocarcinoma drastically improved following neoadjuvant chemotherapy and a liver transplant. The 5-year survival rate was close to 60%, according to a recent study. 'That was significant,' he said. 'And ultimately, our involvement was really to show that this should be a clinical decision between the transplant surgeon and Nathan.' Bokhari said it's unclear if Anthem used AI in Kirkland's claim denials — he becomes suspicious when denials include errors and incorrect terms — but the denials could have also been based on 'incompetent review,' he added. Anthem denies using AI in its coverage decisions. 'AI is not used in denial decisions,' Kiryluik told Medscape Medical News . 'Denial decisions are made by an appropriate medical director through our peer clinician review process.' 'Battle of the Bots' Claimable sits alongside a small but growing number of companies using AI to help physicians and patients fight health coverage denials. In June 2024, Flight Health Insurance launched a platform to help patients appeal denials and, in April 2025, expanded its reach to providers with a platform called Fight Paperwork. In November 2024, Cofactor AI introduced an AI-powered platform called Cofactor Denial Suite that supports claim appeals for providers. In January 2025, payment software company Waystar announced the launch of Waystar AltitudeAI™ to help providers appeal denied medical claims. And in April 2025, Red Sky Health unveiled its new AI-solution, Daniel, which helps providers identify and correct claims errors. Holden Karau, a software development engineer who created Flight Health Insurance, has been thinking about insurance coverage issues since being hit by a car in 2019. While the insurer paid for her 'bones to be fixed,' Karau said nearly every other aspect of the process ended in a payment dispute. Only recently has the technology gotten to a point where it made sense to work on a platform to help fight denials, Karau said. Like Claimable, Karau's company keeps the process simple and the costs low for patients and providers. 'The hope is to keep the prices low because we think that there's just so many denials out there that aren't being appealed,' Karau said. A Hard-Won Transplant That Didn't Come to Pass Six days after the February 6 transplant denial, Kirkland learned that Anthem had reversed its decision based on 'new information.' According to Bokhari, Claimable is currently beating about 85% of health coverage denials. Kiryluik told Medscape Medical News via email that the initial coverage request was 'denied due to lack of medical necessity based on the provided information.' 'After Mr Kirkland contacted us on February 9, we initiated an appeal process, which included further discussions between our oncology medical director and his transplant surgeon,' Kiryluik said in a statement. 'It was during this review that new details were provided, including an updated diagnosis and data on the transplant center's success rates for patients with similar diagnosis,' Kiryluik explained. Claimable's letter, for instance, corrected Kirkland's cancer diagnosis and cited data from Kirkland's transplant team showing that all 10 patients with intrahepatic cholangiocarcinoma who had received a liver transplant at their institution had survived. 'With this new information, Anthem approved coverage for Mr Kirkland's liver transplant and informed him of the decision,' Kiryluik said. But time was not on Kirkland's side. After Anthem reversed its denial, Kirkland's medical team immediately rescheduled his transplant. Physicians knew it was urgent he received his transplant before his cancer metastasized . Kirkland was prepped and headed into surgery on February 14, which he called 'fitting' because the date happened to be National Organ Donor Day. Surgeons opened him up. Before the transplant, his team first wanted to biopsy a retroperitoneal lymph node. The biopsy came back positive for cancer, indicating the tumor had metastasized. Because the lymph node was outside the surgical resection field, Kirkland's cancer would not have been fully removed, even with a liver transplant, explained Tenner. The transplant procedure was cancelled. Kirkland and his family were crushed. A curative liver transplant is now off the table for Kirkland and the goal is to explore palliative therapies to extend his life and give him the best quality possible, Tenner said. His oncology team is also looking into clinical trials for him, she said. But there's a lingering question: Did Kirkland miss the slim window he may have had for curative intent therapy because Anthem's prior authorization process and coverage denials delayed his care? 'There is a chance that had things been approved quicker and a biopsy obtained, the cancer would not have spread at that time, but I can't give you a definitive 'yes' or 'no' on that,' Tenner said. Ultimately, Anthem also reversed its denials of Kirkland's histotripsy procedures after Claimable got involved. Kirkland also believes the social media attention surrounding his case contributed to Anthem's shift. But the insurer told Medscape Medical News that 'Anthem approved coverage of the histotripsy following an external review by an independent peer review organization. Consideration was given to several factors, including the member's unique clinical circumstances and documentation by the treating facility that the member had exhausted all evidence-based therapies, and other alternative medical services were not available outside of a clinical trial.' In late May, Kirkland finally received his first reimbursement check for $97,000 of the $250,000 he had paid. Even the reimbursement process was 'slow and messy,' he said. He is still waiting for the remaining amount, and his surgeon is still waiting to be paid by Anthem, he said. Despite his outcome, Kirkland said he's 'not done fighting.' He hopes his story will draw attention to unfair insurance denials and lead to changes in company policies. In February, he filed an ERISA appeal to Anthem, urging the insurer to make changes in its policies for patients who need liver transplants and FDA-backed histotripsy procedures. 'At this stage, it's more about making sure other people get the opportunity and the care they need to have a better outcome,' he said. 'It shouldn't be such a burden to get treatment.'
Yahoo
24 minutes ago
- Yahoo
Patrick Mahomes' Family Asking for Prayers on Monday
Patrick Mahomes' Family Asking for Prayers on Monday originally appeared on Parade. On the field, Chiefs' quarterback, Patrick Mahomes, may seem superhuman, but off the field he's far from it. When illness strikes a loved one, it's often the great equalizer. No matter how successful or famous one might be, having a sick family member is a reminder that everyone is just human, and that's why the superstar footballer's family is asking for prayers. On Monday, Mahomes' mom, Randi Mahomes, took to Instagram to share the long and painful battle that her cousin's grandson, Luka has been fighting against a complex form of cancer. 'Please join me in continuing to pray for my cousin's grandson,' she captioned the post to her Instagram story. 'Sweet Luka is still fighting Stage L2 intermediate neuroblastoma. He is undergoing chemo and fighting hard. Please pray for this sweet family as they are going through one of the hardest trials of their lives.' Mahomes also wrote, 'If you feel led, here is a link to donate to their family,' and included a link to the family's GoFundMe page. Luka was diagnosed when he was just eight months old, after a large tumor was discovered on his left lung. After receiving surgery to remove the tumor, he immediately began undergoing chemotherapy. His quick diagnosis was due in part to the experience and expertise of his mother, Cassie, an ICU nurse who immediately recognized the severity of his symptoms. However, she will not be able to return to work while Luka remains immunocompromised for fear of bringing home any type of illness that could put his health at further risk, presenting an additional hardship for the family. According to the University of Chicago's Medical Center, 'neuroblastoma is a disease that originates in immature nerve tissue in the adrenal gland or the sympathetic ganglia located near the spinal cord. The majority of children with neuroblastoma are diagnosed before the age of five and more than 95% are diagnosed before they turn 10.' For the Mahomes family, crowdsourced prayers carry just as much weight as donations, though both are more than welcome. Patrick Mahomes' Family Asking for Prayers on Monday first appeared on Parade on Jul 22, 2025 This story was originally reported by Parade on Jul 22, 2025, where it first appeared. Solve the daily Crossword
Yahoo
24 minutes ago
- Yahoo
Zacks Industry Outlook Highlights HCA Healthcare, Tenet Healthcare, Universal Health and Community Health Systems
For Immediate Release Chicago, IL – July 22, 2025 – Today, Zacks Equity Research discusses HCA Healthcare, Inc. HCA, Tenet Healthcare Corp. THC, Universal Health Services, Inc. UHS and Community Health Systems, Inc. CYH. Industry: Hospitals Link: The Zacks Medical-Hospital industry faces mounting challenges, including rising labor costs, supply expenses, regulatory pressures and tightening budgets. Workforce burnout and cybersecurity risks continue to strain operations, while technological innovations offer long-term efficiency gains. Despite near-term headwinds, growing patient volumes may support gradual through mergers and acquisitions remains a key strategy, allowing hospitals to scale operations and increase market share in a fragmented landscape. Leading players HCA Healthcare, Inc., Tenet Healthcare Corp., Universal Health Services, Inc. and Community Health Systems, Inc. are demonstrating resilience by optimizing operations and expanding strategically to stay competitive in a complex and evolving healthcare environment. Industry Overview The Zacks Medical-Hospital industry comprises for-profit hospital companies that provide healthcare through different types of hospitals, such as acute care, rehabilitation and psychiatric. These hospital entities are engaged in internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics, telehealth services, mental health care and diagnostic and emergency services. Revenues of these companies depend on inpatient occupancy levels, medical and ancillary services ordered by physicians and provided to patients, and the volume of outpatient procedures. These hospital companies receive payments for patient services from the government under the Medicare program, Medicaid, or similar programs, managed care plans (including plans offered through the American Health Benefit Exchanges), private insurers and directly from patients. 4 Key Trends to Watch in the Hospital Industry Elective procedures are on the rise, contributing to increased patient volumes across hospitals. U.S. Census Bureau projections show the 65+ population will grow from 17.3% in 2022 to 22.8% by 2050, amplifying demand for healthcare. Health spending is projected to hit $5.3 trillion by 2025, according to the Peterson-KFF Health System Tracker. However, technological advancements are likely to accelerate a shift from inpatient care to outpatient, ambulatory and home-based services, leaving many hospitals with underused beds and a heavy fixed-cost burden. Labor shortage, higher wages, supply chain disruptions and escalating benefit costs continue to squeeze hospital margins. In response, providers are embracing automation, refining staffing models, and renegotiating supplier contracts to manage expenses. Efforts to reduce reliance on contract labor are gaining traction, although burnout challenges persist. Meanwhile, cybersecurity threats are prompting higher insurance premiums, adding to financial strain. A new $50 billion federal fund aims to support rural and underserved hospitals, but several experts note it may fall short of covering broader funding gaps tied to Medicaid reimbursement changes. Hospitals are investing heavily in AI, automation, and real-time analytics to streamline care delivery and reduce operational inefficiencies. These tools are improving clinical outcomes, enhancing patient engagement, and supporting long-term cost savings. Simultaneously, telehealth, accelerated by the pandemic, has become a permanent and vital component of care, particularly for remote and underserved populations. M&A activity has rebounded strongly post-pandemic, as hospitals seek scale, efficiency, and financial resilience. With the industry still highly fragmented, consolidation is being driven by economic recovery, regulatory clarity and the need to adapt to changing care models. Strategic partnerships, technology-driven collaborations, and innovative delivery models are helping hospitals expand capacity and sharpen their competitive edge. Zacks Industry Rank Shows Bearish Outlook The group's Zacks Industry Rank, which is the average of the Zacks Rank of all member stocks, signals challenging near-term prospects. The Zacks Medical-Hospital industry, which is housed within the broader Zacks Medical sector, currently carries a Zacks Industry Rank #181, which places it in the bottom 26% of nearly 250 Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than two to one. The industry's position in the bottom 50% of the Zacks-ranked industries is a result of a negative earnings outlook for the constituent companies in aggregate. Looking at the aggregate earnings estimate revisions, it appears that analysts are becoming pessimistic about this group's earnings growth potential. As a matter of fact, the industry's earnings estimates for 2025 have gone down 0.2% since February-end. Despite the dull near-term prospects of the industry, we will present a few stocks that you may want to watch. But it's worth taking a look at the industry's shareholder returns and current valuation first. Industry Lags S&P 500 But Outperforms Sector The Zacks Medical-Hospital industry has underperformed the Zacks S&P 500 composite while outperforming the broader Medical sector in a year. The industry has gained 4.2% over this period, underperforming the S&P 500's appreciation of 13.1% and outperforming the broader sector's slide of 17.6%. Industry's Current Valuation On the basis of the trailing 12-month EV/EBITDA (Enterprise Value/ Earnings Before Interest Tax Depreciation and Amortization) ratio, which is commonly used for valuing hospital stocks, the industry trades at 7.84X compared with the S&P 500's 17.79X and the sector's 9.72X. Over the past five years, the industry has traded as high as 9.55X and as low as 6.45X, with a median of 8.03X. 4 Hospital Stocks Worth Your Attention HCA Healthcare: The company operates general and acute care hospitals and is well-positioned to benefit from rising patient volumes. Growth in inpatient surgeries, ER visits, and telemedicine is boosting performance and diversifying revenue. Strategic acquisitions and ongoing dividends and buybacks reflect its focus on expansion and shareholder returns. The Zacks Consensus Estimate for one of the biggest for-profit publicly traded hospitals' 2025 EPS indicates 15% year-over-year growth. HCA Healthcare beat earnings estimates in each of the past four quarters, the average surprise being 7.1%. The consensus mark for 2025 revenues signals a 5.7% increase from a year ago. Shares of the company have gained 20.3% over the year-to-date period. It currently has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Tenet Healthcare Corporation: The company operates a wide network of hospitals and facilities, with strong revenue growth driven by its Ambulatory Care and Hospital segments. The USPI unit remains a core growth engine, supported by strategic tuck-in acquisitions that continue to enhance its market position. The Zacks Consensus Estimate for Tenet Healthcare's 2025 and 2026 bottom line indicates 7.2% and 7% year-over-year growth. It beat earnings estimates in all the past four quarters, the average surprise being 26.4%. The consensus mark for 2025 and 2026 revenues is pegged at $20.9 billion and $21.9 billion, signaling an increase from $20.7 billion in 2024. Shares of the company have gained 38.7% over the year-to-date period. It currently has a Zacks Rank #3. Universal Health Services: The company operates acute care hospitals, outpatient centers, and behavioral health facilities, with specialties including autism, addiction, and military-related conditions. Growth is supported by rising patient days, network expansion, added licensed beds and strategic behavioral health joint ventures. The Zacks Consensus Estimate for Universal Health's 2025 and 2026 bottom line is pegged at $19.43 and $21.10 per share, respectively, up 17% and 8.6% year over year, respectively. It beat earnings estimates in three of the past four quarters and missed once, the average surprise being 13.8%. The consensus mark for 2025 and 2026 revenues indicates 8% and 5.2% year-over-year increases. Although shares of Universal Health have declined 5.9% over the year-to-date period, its improving operations are expected to support a future rebound. It currently sports a Zacks Rank #3. Community Health Systems: It operates a national network of acute care hospitals and outpatient centers, benefiting from higher occupancy rates and a growing telehealth focus. It is expanding through hospital acquisitions, enhancing specialty services, and improving efficiency. Strategic divestments of non-core assets aim to boost long-term profitability and cash flow, despite potential short-term impact. The Zacks Consensus Estimate for Community Health Systems' 2025 and 2026 bottom lines indicates 69.9% and 142.1% year-over-year improvements, respectively. The consensus mark for 2025 and 2026 revenues is pegged at $12.3 billion and $12.8 billion, respectively. Shares of Community Health Systems have gained 20% in the past week. It has a Zacks Rank #3 at present. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Universal Health Services, Inc. (UHS) : Free Stock Analysis Report Tenet Healthcare Corporation (THC) : Free Stock Analysis Report Community Health Systems, Inc. (CYH) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
